NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) entered into securities purchase agreements on September 8, 2026, with institutional investors for a registered direct offering. The transaction involves the sale of 2,610,715 shares of common stock, pre-funded warrants to purchase up to 960,715 shares of common stock, and accompanying warrants to purchase up to 3,571,430 shares of common stock.
The offering is priced at $4.20 per share and accompanying warrant. Pre-funded warrants are priced at $4.1999, with an exercise price of $0.0001 per share. The gross proceeds to the Company are estimated to be approximately $15 million, before deducting placement agent fees and other offering expenses.
The Company intends to use the net proceeds for working capital, general corporate purposes, and the redemption of Series A Convertible Preferred Stock. The offering is expected to close on September 10, 2026, subject to customary closing conditions.
Roth Capital Partners, LLC and A.G.P./Alliance Global Partners are acting as co-placement agents. Under the terms of the agreements, the Company has agreed to pay the placement agents a cash fee equal to 7.0% of the gross proceeds.
Additionally, the Company’s Chief Executive Officer and Chief Medical Officer have entered into lock-up agreements, restricting the sale of their shares for a period of 90 days following the closing date.
